[1] Li L, Li F, Qi H, et al. Coexpression of Pdx1 and beta cell insulin in mesenchymal stem cells could promote the differentiation of nestin-positive epithelium-like progenitors and pancreatic islet-like spheroids. Stem Cells Dev. 2008; 17(4):815-823.[2] Chang CF, Hsu KH, Chiou SH, et al. Fibronectin and pellet suspension culture promote differentiation of human mesenchymal stem cells into insulin producing cells. J Biomed Mater Res A. 2008;86(4):1097-1105.[3] Ciceri F, Piemonti L. Bone marrow and pancreatic islets: an old story with new perspectives. Cell Transplant. 2010; 19(12): 1511-1522.[4] Simard AR, Soulet D, Gowing G, et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49(4):489- 502.[5] Lee JK, Jin HK, Endo S, et al. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem Cells. 2010;28(2):329-343.[6] Valle-Prieto A, Conget PA. Conget. Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cells Dev. 2010;19(12):1885-1893.[7] Waterman RS, Betancourt AM. Treating Chronic Pain with Mesenchymal Stem Cells: A Therapeutic Approach Worthy of Continued Investigation. J Stem Cell Res Ther. 2011 S2:001. doi:10.4172/2157-7633.[8] Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008;8(5):569-581.[9] Ho JH, Tseng TC, Ma WH, et al. Multiple intravenous ransplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta cell differentiation in streptozocin-induced diabetic mice. Cell Transplant. 2012;21(5):997-1009.[10] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292: 154-156.[11] Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282: 1145-1147. [12] Assady S, Maor G, Amit M, et al. Insulin production by human embryonic stem cells. Diabetes. 2001;50:1691-1697.[13] Soria B, Roche E, Berná G, et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49(2): 157-162.[14] D'Amour KA, Bang AG, El iazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24: 1392-1401.[15] Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008; 26: 443-452.[16] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fbroblast cultures by defned factors. Cell. 2006;126: 663-676.[17] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell. 2007; 131: 861-872.[18] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.[19] Alipio Z, Liao W, Roemer EJ, et al. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci U S A. 2010;107:13426-13431.[20] Zhang D, Jiang W, Liu M, et al. Highly effcient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 2009; 19: 429-438.[21] Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood. 2003; 102: 3483-3493.[22] Ianus A, Holz GG, Theise ND, et al. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003; 111:843-850.[23] Zhao M, Amiel SA, Ajami S, et al. Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. PLoS One. 2008;3:e2666.[24] Sun Y, Chen L, Hou XG, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (Engl). 2007;120(9):771-776.[25] Xie QP, Huang H, Xu B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation. 2009;77(5):483-491.[26] Bhansali A, Upreti V, Khandelwal N, et al. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus.Stem Cells Dev. 2009; 18: 1407-1416. [27] Estrada EJ, Valacchi F, Nicora E, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008; 17:1295-1304.[28] Gao F, Wu DQ, Hu YH, et al. In vitro cultivation of islet like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res. 2008;151(6):293-302. [29] Prabakar KR, Domínguez-Bendala J, Molano RD, et al. Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant. 2012;21(6);1321-1339.[30] Kadam SS, Bhonde RR. Islet neogenesis from the constitutively nestin expressing human umbilical cord matrix derived mesenchymal stem cells. Islets. 2010;2(2):112-120.[31] Parekh VS, Joglekar MV, Hardikar AA. Differentiation of human umbilical cord blood-derived mononuclear cells to endocrine pancreatic lineage. Differentiation. 2009;78(4): 232-240.[32] Suen PM, Leung PS. Pancreatic stem cells: a glimmer of hope for diabetes? JOP. 2005; 6(5):422-424.[33] Noguchi H, Matsumoto S, Ueda M, et al. Method for isolation of mouse pancreatic stem cells. Transplant Proc. 2008;40(2): 422-423.[34] Zou C, Suen PM, Zhang Y, et al. Isolation and in vitro characterization of pancreatic progenitor cells from the islets of diabetic monkey models. Int J Biochem Cell Biol. 2006;38: 973-984.[35] Bonner-Weir S, Taneja M, Weir GC, et al. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci U S A. 2000; 97: 7999-8004.[36] Gao R, Ustinov J, Pulkkinen MA, et al. Characterization of endocrine progenitor cells and critical factors for their differentiation in human adult pancreatic cell culture. Diabetes. 2003; 52: 2007-2015.[37] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.[38] Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006;98:596-605.[39] Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminalevent in diabetic cardiomyopathy: Restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation. 2005;111: 2073-2085.[40] Jesmin S, Sakuma I, Hattori Y, et al. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol. 2003;23:2021-2026.[41] Camp TM, Tyagi SC, Senior RM, et al. Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia. 2003;46:1438-1445.[42] Zhang N, Li J, Luo R, et al. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes. 2008; 116:104-111.[43] Wang X, Zhao T, Huang W, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells. 2009;27:3021-3031.[44] Hare JM , Traverse JH,Henry TD, et al. A randomized, double-blind,placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54: 2277-2286.[45] Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099-1106.[46] Amin AH, Abd Elmageed ZY, Nair D, et al. Modi?ed multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood ?ow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010;90:985-996.[47] Comerota AJ, Link A, Douville J, et al. Upper extremity ischemia treated with tissue repair cells from adult bone marrow. J Vasc Surg. 2010;52:723-739.[48] Fazan R Jr, Dias da Silva VJ, Ballejo G, et al. Power spectra of arterial pressure and heart rate in streptozotocin-induced diabetes in rats. J Hypertens. 1999;17:489-495.[49] Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14: 631-640.[50] Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA. 2006;103:17438-17443.[51] Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia. 2000;43:957-973.[52] Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57:3099-3107.[53] Medina A, Scott PG, Ghahary A, et al. Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil. 2005;26: 306-319.[54] Spanheimer RG. Correlation between decreased collagen production in diabetic animals and in cells exposed to diabetic serum: Response to insulin. Matrix. 1992;12:101-107.[55] Kwon DS, Gao X, Liu YB, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008;5:453-463.[56] Wu Y, Chen L, Scott PG, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648-2659.[57] Le Blanc K, Pittenger M. Mesenchymal stem cells: Progress toward promise. Cytotherapy. 2005;7:36-45. |